Tuesday, March 12, 2019

The Quality Training Program Offered by ASCO


Wednesday, February 13, 2019

The NCCN Oncology Research Program


Hematologist Dr. Matthew Taub specializes in the diagnosis and treatment of blood cancers. As a physician with Optimum Oncology Hematology Associates, Dr. Matthew Taub follows treatment guidelines released by the National Comprehensive Cancer Network (NCCN).

As of 2018, NCCN has raised more than $30 million for trials of promising treatment options for multiple cancers, including hematologic malignancies, breast cancer, and sarcomas. In collaboration with research cancer centers, NCCN member institutions, and biotechnology and drug development companies, NCCN funds all phases of oncology-focused clinical trials through its Oncology Research Program (ORP). In addition to financial support, NCCN plays a major role in organizing and monitoring trials and results analysis and publishing study results. 

Recently, NCCN ORP was awarded $2 million by healthcare multinational Eli Lilly. The grant will fund research covering the process that underlies CDK4/6 resistance in advanced breast cancer patients.

Thursday, January 24, 2019

The Work of the National Comprehensive Cancer Network


A strong believer in evidence-based medicine, Dr. Matthew Taub has treated people with a variety of cancers over the course of his 20-year career. Practicing at Optimum Oncology Hematology Associates in Pembroke Pines, Florida, Dr. Matthew Taub adheres to the guidelines of the National Comprehensive Cancer Network (NCCN) for decisions regarding chemotherapy and other treatments. 

A large part of the NCCN organization is its Oncology Research Program (ORP), which aims to enhance patient quality of life and reduce cancer-related deaths by advancing research in the field. To work toward its goals, ORP supports oncology preclinical, translational, and clinical research at NCCN member institutions. 

NCCN also actively works with industry drug developers to ensure effective communication across the industry. To date, NCCN ORP has allocated millions of dollars in research grants to fund investigator-initiated trials that push the boundaries of medical knowledge and seek answers to important research questions.

Tuesday, January 15, 2019

Memorial Hospital Miramar Nurtures Babies with Specially Designed NICU


An experienced oncologist and hematologist, Dr. Matthew Taub practices at Optimum Oncology Hematology Associates in Pembroke Pines, Florida. Matthew Taub, MD, is a member of the multidisciplinary committee at Memorial Hospital Miramar.

Located in Miramar, Florida, Memorial Hospital Miramar features a family birthing center and a level II Neonatal Intensive Care Unit (NICU) with 16 private patient rooms. Memorial Hospital Miramar NICU is equipped to care for neonates born at 28 weeks and later. 

The hospital invited a team of doctors, nurses, respiratory therapists, and parents to collaborate on the NICU design, which aims to provide an environment that feels like home. The unit has a special focus on privacy to allow bonding moments that nurture babies. In addition to the latest medical equipment, the NICU features ambient lighting that simulates night and day so babies develop a circadian rhythm that promotes healing and development.

Wednesday, December 26, 2018

Four Types of Benign Tumors


Monday, December 17, 2018

Immunotherapy Side Effects More Common Than Originally Thought


A hematology and an oncology physician at Optimum Oncology Hematology Associates in Pembroke Pines, Florida, Dr. Matthew Taub has won numerous awards for his work treating and managing various disorders in multiple states. Active in his professional community, Dr. Matthew Taub maintains membership with such organizations as the American Society of Clinical Oncology (ASCO).

Since 1964, ASCO has promoted the prevention and cure of cancer through the education of professionals and cancer research. Recently, the organization released information about a new study on people with non-small cell lung cancer (NSCLC). According to this report, unexpected medical problems caused by the immunotherapy checkpoint inhibitors nivolumab, atezolizumab, and pembrolizumab may all be underreported in the initial trials of these therapies.

To complete this analysis, researchers looked at close to 2,800 people diagnosed with NSCLC who received immunotherapy checkpoint inhibitors between 2015 and 2017. These individuals reported adverse events caused by these inhibitors to their insurance companies. This information was available to researchers through OptumLabs Data Warehouse, an insurance database founded in 2012 by the Mayo Clinic.

According to the results, the most common adverse outcome to immunotherapy was hypothyroidism. This issue appeared in just over 9 percent of patients. Meanwhile, acute kidney injury and anemia affected over 8 percent of patients, combined. Some patients also reported cardiac and gastrointestinal events, though these issues were relatively rare.

The researchers believe that being aware of these side effects and when they occur will grant physicians a greater chance to intervene and prevent such issues. In the meantime, being aware of the issues that immunotherapy can cause ensures that patients and physicians alike are better informed about treatment options.

Tuesday, December 11, 2018

Could an App Help Patients Manage Cancer Pain?


A graduate of the Ross University School of Medicine, Dr. Matthew Taub completed postdoctoral training in oncology and hematology at New York Medical College. Based in Florida, Dr. Matthew Taub offers treatment through Everglades Oncology and Hematology in Miramar. He approaches patients with compassion and understands that everyone experiences a cancer diagnosis and treatment side effects differently.

A researcher at Massachusetts General Hospital recently found that a smartphone app called ePAL that makes use of artificial intelligence (AI) could actually help patients manage cancer-related pain. Patients in a study reported an average reduction in pain severity scores of 20 percent after eight weeks of app use, while those individuals in usual care reported no change. Furthermore, among a randomized study involving 112 patients with solid tumors, ePAL reduced the risk of hospital admission by about 70 percent. However, patients using the app did report increased anxiety.

The app helps patients differentiate between severe and moderate pain and connects them to the appropriate resource, whether that is clinical or educational feedback. While more research needs to be done, the findings show the viability of using apps to track and manage cancer-related pain.